Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole in Pediatric GERD
NCT00787891Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of rabeprazole in gastroesophageal reflux disease (GERD), sponsored by Johnson & Johnson. Started Jan 2009; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00787891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787891.